Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CUP

- PMLiVE

Cost containment and the German market

The healthcare system’s budget limitations will face further pressure from challenges such as personalised medicine

- PMLiVE

EMA recruits patient voices for its management board

Continues its drive to embed patients' values within drug assessment

- PMLiVE

Defining value: has anyone asked the patient?

The real-world challenges they face give patients unique views on 'value'

UK flag

UK needs ‘Brexit contingency plan’ to protect its science base

Action must be taken to safeguard life sciences in the country, say MPs

- PMLiVE

A rare opportunity

Sobi’s Neil Dugdale on how the UK’s approach to rare diseases is changing

Roche Basel Switzerland

Roche gets EU okay for Avastin/Tarceva combination

Lung cancer therapy ‘significantly’ extends progression-free survival

Shire Basingstoke

Shire completes $32bn Baxalta merger

Creates world leading rare diseases specialist

EU flag

Second Remicade biosimilar given green light in Europe

Samsung Bioepis’ Flixabi provides another lower-cost treatment option

ABPI London offices

ABPI says UK role as clinical trial hub threatened by Brexit

Warns UK patients could be denied access to medical innovations as a result

- PMLiVE

J&J gets European OK for myeloma therapy Darzalex

First-in-class immunotherapy achieved ‘significant increase’ in overall survival

- PMLiVE

Stronger together

A patient-focused strategy is high on the agenda, with a top-down approach favoured by industry leaders

Actelion HQ Switzerland

Actelion gets EU go-ahead for Uptravi in PAH

Oral therapy predicted to become $1bn-plus product

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links